| Not Yet Recruiting | VLA1553-403 Pregnancy Surveillance Study Chikungunya Virus Infection | — | 2026-03-31 |
| Withdrawn | A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children Chikungunya Virus Infection | Phase 3 | 2026-02-06 |
| Enrolling By Invitation | Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Va Chikungunya Virus Infection | — | 2026-02-02 |
| Enrolling By Invitation | Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the Chikungunya Virus Infection | — | 2026-02-02 |
| Active Not Recruiting | Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for P Chikungunya Virus Infection | — | 2025-09-22 |
| Withdrawn | A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) Chikungunya Virus Infection | Phase 3 | 2024-04-10 |
| Completed | Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine C Zika, Zika Virus Infection | Phase 1 | 2024-03-25 |
| Completed | A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years Chikungunya Virus Infection | Phase 2 | 2023-12-18 |
| Withdrawn | COVID-19 Paediatric VLA2001-321 Study SARS-CoV-2 Infection | Phase 2 / Phase 3 | 2022-10-01 |
| Completed | VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infec SARS-CoV-2 Infection | Phase 2 / Phase 3 | 2022-05-09 |
| Completed | Safety and Immunogenicity of VLA2001 Adults Aged ≥56 Years SARS-CoV-2 Virus Infection | Phase 3 | 2021-08-09 |
| Completed | COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 SARS-CoV-2 Virus Infection | Phase 3 | 2021-04-26 |
| Active Not Recruiting | Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) Chikungunya Virus Infection | Phase 3 | 2021-04-02 |
| Completed | Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Hea Chikungunya Virus Infection | Phase 3 | 2021-02-22 |
| Completed | Dose Finding Study to Evaluate The Safety, Tolerability and Immunogenicity of an Inactiviated, Adjuvanted SARS SARS-CoV-2 Virus Infection | Phase 1 / Phase 2 | 2020-12-16 |
| Completed | Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate i Chikungunya Virus Infection | Phase 3 | 2020-09-17 |
| Completed | Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701 Enterotoxigenic Escherichia Coli Infection, Diarrhea | Phase 2 | 2018-06-04 |
| Completed | Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Vo Chikungunya | Phase 1 | 2018-03-05 |
| Completed | Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika V Zika Virus, Zika Virus Infection | Phase 1 | 2018-02-24 |
| Completed | Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Hea Clostridium Difficile | Phase 2 | 2014-12-01 |
| Withdrawn | Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination Japanese Encephalitis | Phase 1 | 2012-06-01 |
| Completed | Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 Pseudomonas Aeruginosa Infection | Phase 2 / Phase 3 | 2012-03-01 |
| Completed | Safety Surveillance After Immunization With IXIARO Japanese Encephalitis | — | 2011-03-01 |
| Completed | Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country Japanese Encephalitis | Phase 3 | 2010-12-01 |
| Completed | An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 Clostridium Difficile Infection | Phase 1 | 2010-12-01 |
| Completed | Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Populat Japanese Encephalitis | Phase 3 | 2010-10-01 |
| Completed | This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population Japanese Encephalitis | Phase 4 | 2010-06-01 |
| Completed | Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population Encephalitis | Phase 3 | 2010-03-01 |
| Completed | Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Populat Encephalitis | Phase 3 | 2010-01-01 |
| Completed | Open-Label Study Assessing The Safety, Immunogenicity and Dose Response of IC47 Pneumococcal Infections | Phase 1 | 2009-03-01 |
| Completed | Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients Pneumonia, Ventilator-Associated | Phase 2 | 2008-12-01 |
| Completed | Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunt Healthy | Phase 1 | 2008-09-01 |
| Completed | Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling Japanese Encephalitis | Phase 3 | 2008-09-01 |
| Completed | Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis | Phase 3 | 2007-12-01 |
| Completed | Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis | Phase 3 | 2007-12-01 |
| Completed | Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis | Phase 3 | 2006-09-01 |
| Completed | Virological Response Study of the HCV Vaccine IC41 Chronic Hepatitis C | Phase 2 | 2006-02-01 |
| Completed | Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis | Phase 3 | 2005-10-01 |
| Completed | Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis | — | 2005-10-01 |
| Completed | Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis | Phase 3 | 2005-10-01 |
| Completed | Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis | Phase 3 | 2005-09-01 |
| Completed | Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 Japanese Encephalitis | Phase 3 | 2005-09-01 |
| Completed | Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 Japanese Encephalitis | Phase 3 | 2005-09-01 |
| Completed | Phase II Study of Immunization With a Hepatitis C Virus (HCV) Antigen Peptide Vaccine Chronic Hepatitis C | Phase 2 | 2002-11-01 |